Residual Glioma
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO) (NCT04164901) | Institut de Recherches Internationales Servier | 2020-01-05 |
Track Residual Glioma automatically
Every clearance here is in the API, with alerts when new ones post.